California State Teachers Retirement System Sells 6,892 Shares of Lexicon Pharmaceuticals, Inc. (LXRX)
California State Teachers Retirement System cut its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 8.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,335 shares of the biopharmaceutical company’s stock after selling 6,892 shares during the quarter. California State Teachers Retirement System owned approximately 0.07% of Lexicon Pharmaceuticals worth $1,256,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the company. FMR LLC grew its position in shares of Lexicon Pharmaceuticals by 0.9% in the 2nd quarter. FMR LLC now owns 15,785,280 shares of the biopharmaceutical company’s stock worth $259,668,000 after buying an additional 137,421 shares during the period. Vanguard Group Inc. boosted its stake in Lexicon Pharmaceuticals by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock worth $59,773,000 after purchasing an additional 585,222 shares in the last quarter. USS Investment Management Ltd bought a new position in Lexicon Pharmaceuticals in the 2nd quarter worth about $57,705,000. Eagle Asset Management Inc. boosted its stake in Lexicon Pharmaceuticals by 0.3% in the 2nd quarter. Eagle Asset Management Inc. now owns 2,861,065 shares of the biopharmaceutical company’s stock worth $47,064,000 after purchasing an additional 8,756 shares in the last quarter. Finally, State Street Corp boosted its stake in Lexicon Pharmaceuticals by 19.9% in the 2nd quarter. State Street Corp now owns 1,967,255 shares of the biopharmaceutical company’s stock worth $32,363,000 after purchasing an additional 326,088 shares in the last quarter.
In related news, Director Public Equities L.P. Invus bought 145,680 shares of the stock in a transaction on Friday, November 10th. The shares were acquired at an average price of $9.74 per share, for a total transaction of $1,418,923.20. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Lonnel Coats bought 30,000 shares of the stock in a transaction on Friday, September 15th. The shares were bought at an average price of $12.54 per share, for a total transaction of $376,200.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 945,353 shares of company stock worth $9,304,953 in the last 90 days. Company insiders own 5.77% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “California State Teachers Retirement System Sells 6,892 Shares of Lexicon Pharmaceuticals, Inc. (LXRX)” was published by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/california-state-teachers-retirement-system-sells-6892-shares-of-lexicon-pharmaceuticals-inc-lxrx/1721190.html.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) opened at $9.75 on Thursday. Lexicon Pharmaceuticals, Inc. has a one year low of $8.07 and a one year high of $18.00. The company has a quick ratio of 1.65, a current ratio of 1.66 and a debt-to-equity ratio of 1.09.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.07. The business had revenue of $26.94 million for the quarter, compared to analysts’ expectations of $27.97 million. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. The business’s revenue for the quarter was down 2.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.35) EPS. sell-side analysts forecast that Lexicon Pharmaceuticals, Inc. will post -1.45 EPS for the current year.
A number of equities analysts recently issued reports on the stock. Wedbush reiterated an “outperform” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, October 5th. Needham & Company LLC reiterated a “buy” rating and issued a $21.00 price target on shares of Lexicon Pharmaceuticals in a research note on Sunday, September 17th. Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 1st. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 14th. Finally, BidaskClub cut shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 10th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $28.75.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.